Immix Biopharma (IMMX) Non Operating Income (2021 - 2026)

Quarterly results put Non Operating Income at $717168.0 for Q1 2026, up 377.41% from a year ago — trailing twelve months through Mar 2026 was $1.1 million (up 24.77% YoY), and the annual figure for FY2025 was $555526.0, down 45.4%.

Immix Biopharma has reported Non Operating Income over the past 6 years, most recently at $717168.0 for Q1 2026.

  • Non Operating Income reached $717168.0 in Q1 2026 per IMMX's latest filing, up from $216712.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $717168.0 in Q1 2026 and bottomed at -$388.0 in Q1 2022.
  • Median Non Operating Income over the past 5 years was $168035.0 (2024), compared with a mean of $179767.6.
  • The largest annual shift saw Non Operating Income plummeted 98.3% in 2022 before it soared 118309.17% in 2023.
  • Over 5 years, Non Operating Income stood at $14725.0 in 2022, then soared by 1452.29% to $228575.0 in 2023, then fell by 18.69% to $185851.0 in 2024, then increased by 16.61% to $216712.0 in 2025, then surged by 230.93% to $717168.0 in 2026.
  • Business Quant data shows Non Operating Income for IMMX at $717168.0 in Q1 2026, $216712.0 in Q4 2025, and $84539.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 444,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 201.20 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -46.98 Mn
10 Immix Biopharma 476.17 Mn 476.17 Mn - 717,168.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 717,168.00
Dec 31, 2025 216,712.00
Sep 30, 2025 84,539.00
Jun 30, 2025 104,056.00
Mar 31, 2025 150,219.00
Dec 31, 2024 185,851.00
Sep 30, 2024 256,680.00
Jun 30, 2024 306,915.00
Mar 31, 2024 267,908.00
Dec 31, 2023 228,575.00
Sep 30, 2023 186,691.00
Jun 30, 2023 128,848.00
Mar 31, 2023 27,892.00
Dec 31, 2022 14,725.00
Jun 30, 2022 -109.00
Mar 31, 2022 -388.00
Dec 31, 2021 864,114.00
Sep 30, 2021 -53,937.00
Jun 30, 2021 -36,135.00
Mar 31, 2021 -852,544.00